Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2012 | 10:28pm CEST

CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
02:31p CVS PHARMACY : Earns URAC Reaccreditation in Community Pharmacy
01:05p CONSIDER YOUR PURPOSE : PA and PharmD Students Receive Short White Coats
08/16 CVS HEALTH : Prom night at YMCA Camp Oakes
08/16 CVS HEALTH : Survey Reveals Two in Three Americans who plan to get a Flu Shot Be..
08/15 CVS : Promoting Medication Adherence
08/11 FARUQI & FARUQI, LLP : is Investigating CVS Health Corporation (CVS) on Behalf o..
08/11 CVS : Delivering The Right Care at the Right Time
08/10 CVS : Recruiting Mature Workers
08/10 CVS : Talent Is Ageless
08/09 CVS tops 2Q forecasts despite sales slump
More news
News from SeekingAlpha
12:51p TARGET REPORTS Q2 : Updating My Bullish Comments From Last Month
07:35a Bert's August Dividend Stock Watch List
05:04a CVS HEALTH VS. WALGREENS BOOTS ALLIA : Which Drugstore Is The 'Best' Buy Now?
08/16 CVS Is Going Back Towards $100
08/15 BETTER DIVIDEND GROWTH STOCK BUY TOD : CVS Or Walgreens Boots Alliance?
Financials ($)
Sales 2017 184 098 M
EBIT 2017 10 053 M
Net income 2017 5 304 M
Debt 2017 24 744 M
Yield 2017 2,49%
P/E ratio 2017 15,74
P/E ratio 2018 13,45
EV / Sales 2017 0,57x
EV / Sales 2018 0,55x
Capitalization 80 563 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 86,6 $
Spread / Average Target 9,3%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH0.43%80 563
WALGREENS BOOTS ALLIANCE-1.97%86 956
EXPRESS SCRIPTS HOLDING CO-9.87%35 808
MCKESSON CORPORATION5.12%31 043
CARDINAL HEALTH INC-7.70%20 889
AMERISOURCEBERGEN CORP.2.31%17 535